Patent SG-11201903450Y-A (SG)
Title: Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
Inventor: HAN HQ
IPC: A61K38/18
Filed: 2017-10-19
Abstract: nM 10 nM 100 pM FIG 12 WT Ac t RIIB WT Ac t RIIA r- O BMP9 Bin d ing S ig na l ( Vo lts) 4 8 6 2 0 cc WT Ac t RIIA 0.0 rn 2 co WT Ac t RIIB WT Ac t RIIA O O 9 9 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT 111110m°III III °III (10) International Publication Number WO 2018/075747 Al (51) International Patent Classification: A61K 38/17 (2006.01) A61P 9/10 (2006.01) A61K 38/18 (2006.01) A61P 9/12 (2006.01) A61P 3/00 (2006.01) A61P 19/00 (2006.01) A61P 9/00 (2006.01) (21) International Application Number: PCT/US2017/057351 (22) International Filing Date: 19 October 2017 (19.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/410,595 20 October 2016 (20.10.2016) US (71) Applicant: ALIVEGEN USA, INC. [US/US]; 810 Lawrence Drive, Suite 120, Thousand Oaks, CA 91320 (US). (72) Inventors: HAN, Hq; 3353 Crossland Street, Thousand Oaks, CA 91320 (US). ZHOU, Xiaolan; 3876 Rodene Street, Newbury Park, CA 91320 (US). (74) Agent: CRANDALL, Craig, A.; 3034 Deer Valley Av- enue, Newbury Park, CA 91320 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: METHODS FOR TREATING MUSCLE WASTING AND BONE DISEASE USING NOVEL HYBRID ACTRIIB LI- = GAND TRAP PROTEINS 1-1 N 71' N N O GC O 1-1 N O (57) : The present disclosure describes novel hybrid soluble ActRIIB-ECD polypeptides. The present disclosure provides methods for treating or preventing muscle wasting, bone disease, a metabolic, fibrosis, an autoimmune/inflammatory, cardiovascular disease, cancer or cancer, chronic kidney disease (CKD), arthritis, anorexia, liver disease, organ or tissue transplant rejection, anemia, pain, and/or aging in a subject in need thereof. Further, the present disclosure provides methods of inducing stem cell growth for tissue repair or organ regeneration in a subject. The aforementioned methods comprising administering to the subject a therapeutically effective amount of a hybrid ActRIIB ligand trap polypeptide. The present disclosure also provides pharmaceutical compositions comprising hybrid ActRIIB ligand trap polypeptides. [Continued on next page] WO 2018/075747 Al MIDEDIMOMOIDEIREIDIONOMMEHOHINVOIMIE UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))